ID   SJ-HGGX42c
AC   CVCL_C1NL
SY   SJHGG054830_C2
DR   cancercelllines; CVCL_C1NL
DR   Wikidata; Q114313026
RX   PubMed=34215733;
WW   https://pbtp.stjude.cloud/sample-details/29986/baker/SJHGG059115/SJ-HGGX42/Cell%20Line
CC   Characteristics: Derived from a patient-derived xenograft.
CC   Doubling time: 6.1 days (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; 20893; BCOR; Simple; p.Ser177fs (c.529_530delAG); Zygosity=Heterozygous (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Gly35Arg (c.103G>A) (H3.3G34R); ClinVar=VCV000438766; Zygosity=Heterozygous (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu265del (c.792_794delTCT); Zygosity=Heterozygous (PubMed=34215733).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P08659; Firefly luciferase.
CC   Genetic integration: Method=Transfection/transduction; Gene=FPbase; 8DNLG; YFP (Note=EYFP, yellow fluorescent protein derived from GFP).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Brain, cerebral cortex; UBERON=UBERON_0000956.
ST   Source(s): PubMed=34215733
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 13
ST   D16S539: 9,11
ST   D18S51: 12,18
ST   D21S11: 29,30
ST   D3S1358: 14,15
ST   D5S818: 13
ST   D7S820: 11,12
ST   D8S1179: 13
ST   TH01: 6,9.3
ST   TPOX: 9,11
ST   vWA: 17,18
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   13-14Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 10-09-24; Version: 6
//
RX   PubMed=34215733; DOI=10.1038/s41467-021-24168-8; PMCID=PMC8253809;
RA   He C., Xu K., Zhu X.-Y., Dunphy P.S., Gudenas B., Lin W.-W., Twarog N.,
RA   Hover L.D., Kwon C.-H., Kasper L.H., Zhang J.-Y., Li X.-Y., Dalton J.,
RA   Jonchere B., Mercer K.S., Currier D.G., Caufield W., Wang Y.-Z., Xie J.,
RA   Broniscer A., Wetmore C., Upadhyaya S.A., Qaddoumi I., Klimo P.,
RA   Boop F., Gajjar A., Zhang J.-H., Orr B.A., Robinson G.W., Monje M.,
RA   Freeman B.B. 3rd, Roussel M.F., Northcott P.A., Chen T.-S., Rankovic Z.,
RA   Wu G., Chiang J.C.-H., Tinkle C.L., Shelat A.A., Baker S.J.;
RT   "Patient-derived models recapitulate heterogeneity of molecular
RT   signatures and drug response in pediatric high-grade glioma.";
RL   Nat. Commun. 12:4089.1-4089.17(2021).
//